Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Sanofi ( (SNY) ) is now available.
On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. If approved, Dupixent would be the first targeted medicine for CSU in the EU in over a decade. This advancement could enhance Sanofi’s market position in the EU and provide new treatment options for patients with CSU who have inadequate responses to existing therapies.
The most recent analyst rating on (SNY) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by its strong earnings call performance and attractive valuation, which are offset by bearish technical indicators and moderate financial performance. The company’s strategic initiatives and positive sales outlook contribute significantly to its score, despite some challenges in cash flow and market momentum.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a research and development-driven, AI-powered biopharmaceutical company dedicated to improving lives through innovative medicines and vaccines. With a focus on the immune system, Sanofi aims to address urgent healthcare, environmental, and societal challenges. The company is listed on EURONEXT and NASDAQ.
Average Trading Volume: 2,479,359
Technical Sentiment Signal: Hold
Current Market Cap: $115.1B
Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.